MODERNA INC (MRNA)

US60770K1079 - Common Stock

39.39  -0.17 (-0.43%)

After market: 39.64 +0.25 (+0.63%)

Fundamental Rating

3

MRNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRNA is valued expensive and it does not seem to be growing.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

MRNA had negative earnings in the past year.
In the past year MRNA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: MRNA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MRNA reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of MRNA (-14.07%) is better than 84.25% of its industry peers.
With an excellent Return On Equity value of -18.65%, MRNA belongs to the best of the industry, outperforming 86.19% of the companies in the same industry.
Industry RankSector Rank
ROA -14.07%
ROE -18.65%
ROIC N/A
ROA(3y)18.74%
ROA(5y)2.74%
ROE(3y)31.99%
ROE(5y)4.61%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MRNA has a Gross Margin of 78.43%. This is amongst the best in the industry. MRNA outperforms 86.19% of its industry peers.
MRNA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.72%
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRNA has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, MRNA has more shares outstanding
The debt/assets ratio for MRNA has been reduced compared to a year ago.

2.2 Solvency

MRNA has an Altman-Z score of 3.79. This indicates that MRNA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of MRNA (3.79) is better than 77.70% of its industry peers.
MRNA has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
MRNA has a worse Debt to Equity ratio (0.05) than 62.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 3.79
ROIC/WACCN/A
WACC11.84%

2.3 Liquidity

MRNA has a Current Ratio of 4.39. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.39, MRNA perfoms like the industry average, outperforming 50.27% of the companies in the same industry.
MRNA has a Quick Ratio of 4.20. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
MRNA has a Quick ratio (4.20) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.2

More info and screens

3

3. Growth

3.1 Past

MRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.75%, which is quite impressive.
MRNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -44.29%.
The Revenue has been growing by 119.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)37.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.31%
Revenue 1Y (TTM)-44.29%
Revenue growth 3Y104.31%
Revenue growth 5Y119.3%
Sales Q2Q%1.69%

3.2 Future

The Earnings Per Share is expected to grow by 13.91% on average over the next years. This is quite good.
MRNA is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.22% yearly.
EPS Next Y23.75%
EPS Next 2Y12.64%
EPS Next 3Y13.45%
EPS Next 5Y13.91%
Revenue Next Year-49.25%
Revenue Next 2Y-31.73%
Revenue Next 3Y-16.3%
Revenue Next 5Y-0.22%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

MRNA's earnings are expected to grow with 13.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.64%
EPS Next 3Y13.45%

More info and screens

0

5. Dividend

5.1 Amount

MRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

NASDAQ:MRNA (12/20/2024, 8:25:34 PM)

After market: 39.64 +0.25 (+0.63%)

39.39

-0.17 (-0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-20 2025-02-20/amc
Inst Owners67.6%
Inst Owner Change-1.13%
Ins Owners13.36%
Ins Owner Change-0.21%
Market Cap15.16B
Analysts68.24
Price Target77.99 (97.99%)
Short Float %11.73%
Short Ratio5.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.53%
Min EPS beat(2)3.51%
Max EPS beat(2)101.54%
EPS beat(4)4
Avg EPS beat(4)69.14%
Min EPS beat(4)3.51%
Max EPS beat(4)155.49%
EPS beat(8)6
Avg EPS beat(8)-1.23%
EPS beat(12)9
Avg EPS beat(12)4.31%
EPS beat(16)11
Avg EPS beat(16)-2.34%
Revenue beat(2)2
Avg Revenue beat(2)62.39%
Min Revenue beat(2)46.04%
Max Revenue beat(2)78.74%
Revenue beat(4)4
Avg Revenue beat(4)50.79%
Min Revenue beat(4)10.45%
Max Revenue beat(4)78.74%
Revenue beat(8)7
Avg Revenue beat(8)36.35%
Revenue beat(12)10
Avg Revenue beat(12)27.64%
Revenue beat(16)12
Avg Revenue beat(16)25.32%
PT rev (1m)-21.13%
PT rev (3m)-37.86%
EPS NQ rev (1m)-18.86%
EPS NQ rev (3m)-876.72%
EPS NY rev (1m)1.45%
EPS NY rev (3m)-0.35%
Revenue NQ rev (1m)-10.87%
Revenue NQ rev (3m)-54.03%
Revenue NY rev (1m)0.81%
Revenue NY rev (3m)0.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.98
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB 1.28
EV/EBITDA N/A
EPS(TTM)-5.82
EYN/A
EPS(NY)-9.07
Fwd EYN/A
FCF(TTM)-10.28
FCFYN/A
OCF(TTM)-8.33
OCFYN/A
SpS13.2
BVpS30.99
TBVpS30.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.07%
ROE -18.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.43%
FCFM N/A
ROA(3y)18.74%
ROA(5y)2.74%
ROE(3y)31.99%
ROE(5y)4.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.72%
GM growth 5YN/A
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 226.28%
Cap/Sales 14.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.2
Altman-Z 3.79
F-Score3
WACC11.84%
ROIC/WACCN/A
Cap/Depr(3y)117.07%
Cap/Depr(5y)134.11%
Cap/Sales(3y)4.65%
Cap/Sales(5y)15.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.31%
EPS Next Y23.75%
EPS Next 2Y12.64%
EPS Next 3Y13.45%
EPS Next 5Y13.91%
Revenue 1Y (TTM)-44.29%
Revenue growth 3Y104.31%
Revenue growth 5Y119.3%
Sales Q2Q%1.69%
Revenue Next Year-49.25%
Revenue Next 2Y-31.73%
Revenue Next 3Y-16.3%
Revenue Next 5Y-0.22%
EBIT growth 1Y19.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.01%
EBIT Next 3Y14.66%
EBIT Next 5Y16.78%
FCF growth 1Y-163.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-148.38%
OCF growth 3YN/A
OCF growth 5YN/A